CCDC6 and non-small cell lung carcinoma: Therefore, these authors proposed CCDC6 as a predictive biomarker for PARP1 targeting therapy, and they showed that a low CCDC6 protein expression (in 51 out of 138 patients) was correlated with lymph node positivity, DFS and OS in the patients with NSCLC, a finding differing from ours in the HCC group.